COMPARISON OF LONG-TERM CYCLOPHOSPHAMIDE (CY) AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)

被引：0
|
作者：
Koneva, O. [1 ]
Ovsyannikova, O. [1 ]
Desiniva, O. [1 ]
Garzanova, L. [1 ]
Ananieva, L. [1 ]
Starovoytova, M. [1 ]
机构：
[1] Nasonova Res Inst Rheumatol, Moscow, Russia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.4445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0505
引用
收藏
页码：1108 / 1109
页数：2
相关论文
共 50 条
  • [1] COMPARISON OF THE RITUXIMAB(RTM) IN MONOTHERAPY REGIMEN AND MYCOPHENOLATE MOFETIL (MMF) EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 704 - 704
  • [2] COMPARISON OF THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE (SP) AND RITUXIMAB (RTM) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    CHEST, 2020, 157 (06) : 373A - 373A
  • [3] LONG-TERM OUTCOME OF A TARGETED TREATMENT REGIMEN WITH IV CYCLOPHOSPHAMIDE (CYC) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND INTERSTITIAL LUNG DISEASE (ILD)
    Ottewell, Lesley
    Walker, Karen
    Griffiths, Bridget
    RHEUMATOLOGY, 2009, 48 : I76 - I76
  • [4] MYCOPHENOLATE MOFETIL (MMF) IN SCLERODERMA (SSc) ASSOCIATED INTERSTITIAL LUNG DISEASE (ILD) AND SKIN DISEASE - THE AUSTRALIAN EXPERIENCE
    Jayaweera, S.
    Sahhar, J.
    Englert, H.
    Proudman, S.
    Hill, C.
    Youssef, P.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 11 - 11
  • [5] Treatment of systemic sclerosis with severe interstitial lung disease (ILD) unresponsive to cyclophosphamide (CYC) with mycophenolate mofetil (MMIT).
    Mouthon, L
    Valeyre, D
    Brauner, M
    Lamberto, C
    André, MH
    Mahr, A
    Guillevin, L
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S559 - S559
  • [6] MYCOPHENOLATE MOPHETIL IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE (SSC-ILD) IN PATIENTS UNRESPONSIVE TO CYCLOPHOSPHAMIDE (CYC)
    Cuomo, G.
    Abignano, G.
    Iudici, M.
    Petrillo, A.
    Valentini, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S167 - S167
  • [7] EFFICACY AND SAFETY OF LONG TERM CYCLOPHOSPHAMIDE TREATMENT FOR INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
    Kwon, H. M.
    Karig, E. H.
    Go, D. J.
    Park, J. K.
    Lee, E. Y.
    Song, Y. W.
    Lee, H. -J.
    Lee, E. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1011 - 1011
  • [8] Efficacy and Safety of Mycophenolate (MMF) Vs Oral Cyclophosphamide (CYC) for Treatment of Scleroderma-Interstitial Lung Disease (Ssc-ILD): Results of Scleroderma Lung Study II
    Tashkin, Donald
    Roth, Michael
    Clements, Philip
    Furst, Daniel
    Khanna, Dinesh
    Goldin, Jonathan
    Kleerup, Eric
    Arriola, Edgar
    Tseng, Chi-Hong
    Elashoff, Robert
    CHEST, 2015, 148 (04)
  • [9] COMPARISON OF THE RITUXIMAB (RTM) IN MONOTHERAPY REGIMEN AND CYCLOPHOSPHOMIDE (CYP) EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSC) WITH INTERSTITIAL LUNG DISEASE (ILD)
    Koneva, O.
    Ananieva, L.
    Garzanova, L.
    Desinova, O.
    Ovsyannikova, O.
    Starovoytova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1584 - 1585
  • [10] RITUXIMAB AND CYCLOPHOSPHAMIDE COMPARISON FOR EFFICACY AND SAFETY IN THE PATIENTS WITH SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE
    Koneva, Olga
    Ananyeva, Lidia P.
    Garzanova, Liudmila
    Desinova, Oxana
    Ovsyannikova, Olga
    Starovoytova, Mayya
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 169 - 169
12345